Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab biosimilar - Mabion

Next Previous
Search
Drug Profile

Rituximab biosimilar - Mabion

Alternative Names: MabionCD20

Latest Information Update: 18 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabion
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Preregistration Submission Withdrawal Rheumatoid arthritis

Most Recent Events

  • 03 Aug 2023 Mabion withdraws a phase III MABRIDGE trial prior to enrolment in Rheumatoid arthritis (In adults, In the elderly) in Belgium (IV) due to the study being closed for business reasons (NCT04680962) (EudraCT2020-002765-34)
  • 20 Sep 2021 Mabion plans the phase III MABRIDGE trial in Rheumatoid arthritis in March 2021 (NCT04680962) (IV, Infusion)
  • 16 Nov 2020 Upjohn has merged with Mylan to form Viatris

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top